7 Amendments of Ignazio CORRAO related to 2020/2071(INI)
Amendment 14 #
Draft opinion
Recital A a (new)
Recital A a (new)
A a. A. Whereas causes underlying medicines shortages are complex and multi-dimensional and are linked to manufacturing problems, industry quotas, legal parallel trade, but also to economic aspects, such as pricing;
Amendment 69 #
Draft opinion
Paragraph 2
Paragraph 2
2. Calls on the Commission to consider proposinge requirements for the pharmaceutical industry to ensure that its supply chain is diversified and to put in place a medicine shortage risk mitigation plan to manage and overcome any vulnerabilities in and risks toy, disruption or bottleneck in the supply chain;
Amendment 87 #
Draft opinion
Paragraph 3
Paragraph 3
3. Stresses the urgent need for the EU to reduce its over-reliance on a small number of third countries for medicine manufacturing and as sources of key starting materials, intermediate materials and active pharmaceutical ingredients;
Amendment 104 #
Draft opinion
Paragraph 4
Paragraph 4
4. Encourages the Commission to propose measures, including financial incentives, to promote green manufacturing, within the EU, of medicines and of strategically important chemicals used in medicine production; urges the Commission to also propose measures to incentivise the greater inclusion of EU small and medium-sized enterprises in the medicine supply chain given their key role in research and innovation and inherent ability to quickly adapt their production focus, with a view to coping better with unexpected shocks;
Amendment 110 #
Draft opinion
Paragraph 4 a (new)
Paragraph 4 a (new)
4 a. Acknowledges that parallel trade may cause medicines shortages; calls on the Commission and Member States to adequately tackle problems related to parallel trade in medicines in the EU adopting measures based on the highest human rights standards in order to guarantee full availability and accessibility for all medicines, with particular attention to those needed for serious diseases;
Amendment 131 #
Draft opinion
Paragraph 5 a (new)
Paragraph 5 a (new)
5 a. Recalls the detrimentally high level of public dependency on the will of private companies to develop life-saving products; calls for a review of the incentives put in place to encourage research on ‘orphan medicines’ in order to determine whether they are successful, and calls for new incentives should this not be the case;
Amendment 136 #
Draft opinion
Paragraph 5 b (new)
Paragraph 5 b (new)
5 b. Calls on the Commission, in close cooperation with the Member States, to promote andf acilitate greater public transparency, information and best practice sharing and cooperation in regard to pricing, reimbursement and procurement of medicines; calls for a new Transparency Directive to replace Directive 89/105/EEC with the aim of ensuring effective controls and full transparency on the procedures used to determine the prices and the reimbursement of medicinal products in the Member States;